Viatris
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australi...
Latest News
4 days ago · prnewswire.com
Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive YearPITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year, recognizing the Company's commitment to fostering a workplace where colleagues feel valued, supported and empowered to make an impact. The list recognizes 25 global organizations based on Great Place To Work's (GPTW) rigorous assessment process, which includes confidential employee feedback.
5 days ago · prnewswire.com
Viatris to Participate in Upcoming Investor ConferencesPITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare conferences. The UBS Global Biopharma Conference on November 17, 2026, at 10 a.m.
6 days ago · zacks.com
VTRS or DHR: Which Is the Better Value Stock Right Now?Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
6 days ago · zacks.com
Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
11 days ago · zacks.com
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
11 days ago · zacks.com
Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 EarningsThe headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
11 days ago · seekingalpha.com
Viatris Inc. (VTRS) Q3 2026 Earnings Call TranscriptViatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/YVTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
12 days ago · zacks.com
Viatris (VTRS) Q3 Earnings Beat EstimatesViatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.
12 days ago · prnewswire.com
Viatris Reports Third-Quarter 2026 Financial ResultsDelivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Nov. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results. Executive Commentary "Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," said Scott A.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VTRS